Aileen X Wang, MD
Nephrology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 12
- 1 carrier
- Offices
- 2
Offices
2 locations · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
12 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Wang’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A161369 · Current
Licensed to practise in California · since 2019 · expires 2027-03-31 · Eastern Virginia Medical School.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$29,301
Medicare paid this office $29,301 for 151 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 74 | $12,840 | $114 |
| Return visit (30+ min) | 31 | $3,720 | $81 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 18 | $2,032 | $64 |
| Return visit (30+ min) | 14 | $1,732 | $124 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 15 | $1,680 | $105 |
See all 9 services
| Long return visit (40+ min) | 74 | $12,840 | $114 |
| Return visit (30+ min) | 31 | $3,720 | $81 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 18 | $2,032 | $64 |
| Return visit (30+ min) | 14 | $1,732 | $124 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 15 | $1,680 | $105 |
| Needle biopsy of kidney | 13 | $1,265 | $97 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 11 | $1,237 | $95 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 47 | $825 | $13 |
| Ultrasonic guidance for needle placement | 13 | $313 | $24 |
Who their Medicare patients are
151 Original Medicare patients in 2024. Average age 59 · Under 65 58% · 85 and older 0% · Women 46% · Also on Medicaid 57% · Health risk score 5.24. Above the middle of the specialty; the typical nephrology clinician is at 4.01.
Conditions among them: High blood pressure 75% · Chronic kidney disease 75% · Diabetes 54% · Coronary heart disease 40% · Heart failure 26% · Depression 19% · Atrial fibrillation 16% · Cancer 11% · COPD 9% · Stroke 7%.
The office billed $168,693, Medicare allowed $37,933 and paid $29,301; for 360 services of 15 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 151 | 360 | 59 | 5.24 | $168,693 | $29,301 |
| 2023 | 125 | 383 | 56 | 6.77 | $243,260 | $35,310 |
| 2022 | 109 | 310 | 55 | 6.41 | $190,445 | $29,420 |
| 2021 | 72 | 216 | 57 | 6.66 | $90,244 | $19,203 |
| 2020 | 33 | 75 | 63 | 6.56 | $27,265 | $6,030 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 7 services
| Long return visit (40+ min) | 62 | $20,417 | $113 |
| Return visit (30+ min) | 25 | $2,925 | $81 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 25 | $2,897 | $66 |
| Needle biopsy of kidney | 25 | $2,603 | $104 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 16 | $2,377 | $99 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 11 | $754 | $69 |
| Ultrasonic guidance for needle placement | 26 | $657 | $25 |
2022: 7 services
| Long return visit (40+ min) | 52 | $14,288 | $113 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 30 | $4,458 | $84 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 18 | $2,931 | $163 |
| Needle biopsy of kidney | 20 | $2,093 | $105 |
| Return visit (30+ min) | 12 | $1,185 | $74 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 13 | $1,052 | $58 |
| Ultrasonic guidance for needle placement | 20 | $510 | $26 |
2021: 3 services
| Return visit (30+ min) | 38 | $8,110 | $84 |
| Long return visit (40+ min) | 18 | $4,010 | $122 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 11 | $2,631 | $85 |
2020: 2 services
| Return visit (30+ min) | 21 | $4,325 | $72 |
| New patient visit (45+ min) | 11 | $1,308 | $119 |
Medicaid work
$378 in 2021
Medicaid paid $378 for 35 billed services this clinician did in 2021, up to 13 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 35 | $378 |
| 2021 | 35 | 1 | 13 | $378 |
Drugs they prescribed that Part D paid
$227,734
Pharmacies billed $227,734 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 865) in 2024. At or below the middle of the specialty; the typical nephrology clinician is at 0%.
740 generic and 108 brand-name prescriptions · $227,734 in drug cost · 34 antibiotic prescriptions to 19 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Prevymis | 22 | $151,677 | $6,894 |
| Lokelma | 25 | $28,292 | $1,132 |
| Rybelsus | 12 | $10,390 | $866 |
| Atovaquone | 11 | $4,475 | $407 |
| Tacrolimus | 21 | $1,385 | $66 |
See all 23 drugs
| Prevymis | 22 | $151,677 | $6,894 |
| Lokelma | 25 | $28,292 | $1,132 |
| Rybelsus | 12 | $10,390 | $866 |
| Atovaquone | 11 | $4,475 | $407 |
| Tacrolimus | 21 | $1,385 | $66 |
| Cinacalcet | 37 | $1,333 | $36 |
| Valganciclovir | 21 | $1,161 | $55 |
| Mycophenolate Mofetil | 21 | $867 | $41 |
| Fluconazole | 23 | $723 | $31 |
| Pravastatin | 72 | $369 | $5 |
| Hydralazine | 41 | $330 | $8 |
| Carvedilol | 58 | $297 | $5 |
| Atorvastatin | 33 | $207 | $6 |
| Pantoprazole | 37 | $187 | $5 |
| Prednisone | 46 | $150 | $3 |
| Amlodipine Besylate | 72 | $147 | $2 |
| Famotidine | 48 | $111 | $2 |
| Potassium Chloride | 12 | $100 | $8 |
| Gabapentin | 17 | $95 | $6 |
| Sulfamethoxazole-Trimethoprim | 19 | $72 | $4 |
| Metoprolol | 18 | $55 | $3 |
| Lisinopril | 18 | $32 | $2 |
| Losartan | 13 | $13 | $1 |
Year by year
| 2024 | 865 | 120 | 0% (0) | 12% | $227,734 |
| 2023 | 861 | 134 | 0% (0) | 12% | $193,151 |
| 2022 | 751 | 164 | 0% (0) | 12% | $132,852 |
| 2021 | 418 | 85 | 0% (0) | None | $73,699 |
| 2020 | 62 | 23 | None | None | $7,687 |
| 2019 | 75 | 24 | 0% (0) | 15% | $1,259 |
| 2018 | 121 | 36 | 0% (0) | None | $4,005 |
| 2017 | 148 | 38 | None | 16% | $5,914 |
| 2016 | 147 | 32 | None | None | $12,516 |
| 2015 | 276 | 53 | 6% (16) | None | $19,980 |
| 2014 | 68 | 14 | None | 16% | $1,710 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 24 drugs
| Cinacalcet | 30 | $42,750 | $1,425 |
| Lokelma | 33 | $33,514 | $1,016 |
| Atovaquone | 25 | $25,370 | $1,015 |
| Procrit | 13 | $18,535 | $1,426 |
| Tacrolimus | 18 | $9,591 | $533 |
| Valganciclovir | 23 | $4,846 | $211 |
| Mycophenolate Mofetil | 28 | $1,836 | $66 |
| Fluconazole | 33 | $1,517 | $46 |
| Pravastatin | 45 | $748 | $17 |
| Amlodipine Besylate | 55 | $579 | $11 |
| Carvedilol | 42 | $551 | $13 |
| Atorvastatin | 46 | $524 | $11 |
| Terazosin | 14 | $518 | $37 |
| Metoprolol | 29 | $515 | $18 |
| Hydralazine | 35 | $511 | $15 |
| Pantoprazole | 35 | $449 | $13 |
| Famotidine | 45 | $369 | $8 |
| Tamsulosin | 27 | $319 | $12 |
| Sulfamethoxazole-Trimethoprim | 29 | $293 | $10 |
| Prednisone | 34 | $284 | $8 |
| Omeprazole | 24 | $228 | $10 |
| Clonidine | 13 | $166 | $13 |
| Ciprofloxacin | 11 | $80 | $7 |
| Lisinopril | 11 | $26 | $2 |
2022: 21 drugs
| Cinacalcet | 53 | $49,393 | $932 |
| Procrit | 11 | $13,808 | $1,255 |
| Atovaquone | 17 | $13,755 | $809 |
| Novolog Flexpen | 12 | $6,992 | $583 |
| Valganciclovir | 23 | $6,513 | $283 |
| Lantus Solostar | 15 | $6,123 | $408 |
| Tacrolimus | 23 | $5,792 | $252 |
| Mycophenolic Acid | 11 | $3,779 | $344 |
| Mycophenolate Mofetil | 19 | $1,289 | $68 |
| Pravastatin | 83 | $933 | $11 |
| Ultra-Fine Nano Pen Needle | 11 | $656 | $60 |
| Amlodipine Besylate | 64 | $546 | $9 |
| Carvedilol | 32 | $502 | $16 |
| Famotidine | 56 | $404 | $7 |
| Pantoprazole | 22 | $323 | $15 |
| Atorvastatin | 39 | $282 | $7 |
| Metoprolol | 22 | $208 | $9 |
| Losartan | 17 | $186 | $11 |
| Rosuvastatin | 12 | $135 | $11 |
| Furosemide | 21 | $126 | $6 |
| Sulfamethoxazole-Trimethoprim | 11 | $55 | $5 |
2021: 11 drugs
| Cinacalcet | 36 | $18,070 | $502 |
| Atovaquone | 21 | $11,628 | $554 |
| Ozempic | 11 | $9,799 | $891 |
| Famotidine | 21 | $903 | $43 |
| Amlodipine Besylate | 32 | $267 | $8 |
| Pravastatin | 24 | $251 | $10 |
| Carvedilol | 24 | $196 | $8 |
| Pantoprazole | 14 | $195 | $14 |
| Atorvastatin | 41 | $146 | $4 |
| Levothyroxine | 11 | $93 | $8 |
| Prednisone | 11 | $81 | $7 |
2018: 2 drugs
| Amlodipine Besylate | 12 | $286 | $24 |
| Calcitriol | 21 | $222 | $11 |
2017: 2 drugs
| Amlodipine Besylate | 17 | $190 | $11 |
| Losartan | 14 | $122 | $9 |
2016: 1 drug
| Atorvastatin | 17 | $298 | $18 |
2015: 4 drugs
| Gabapentin | 16 | $354 | $22 |
| Atorvastatin | 15 | $284 | $19 |
| Metoprolol | 11 | $48 | $4 |
| Lisinopril | 11 | $38 | $3 |
Money from drug and device companies
$581 in 2025
| 2025 | 2 | 7 | None | $581 |
| 2024 | 2 | 2 | None | $133 |
| 2023 | 5 | 6 | None | $509 |
| 2022 | 6 | 11 | None | $545 |
| 2021 | 2 | 3 | None | $157 |
| 2019 | 1 | 3 | None | $1,431 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Apellis Pharmaceuticals | None | $551 | 6 payments
|
| Ardelyx | Ibsrela | $29 | 1 payment
|
See all 7 published payments
| Ardelyx | Meals · 2025-11-07 | Ibsrela | $29 |
| Apellis Pharmaceuticals | Meals · 2025-11-07 | None | $96 |
| Apellis Pharmaceuticals | Meals · 2025-08-05 | None | $136 |
| Apellis Pharmaceuticals | Meals · 2025-07-17 | None | $25 |
| Apellis Pharmaceuticals | Meals · 2025-07-17 | None | $79 |
| Apellis Pharmaceuticals | Meals · 2025-07-16 | None | $124 |
| Apellis Pharmaceuticals | Meals · 2025-06-18 | None | $92 |
See earlier years (2024, 2023, 2022, 2021, 2019)
2024: $133
| Alexion Pharmaceuticals | None | $113 | 1 payment
|
| Lilly USA | Jardiance | $19 | 1 payment
|
2023: $509
| Alexion Pharmaceuticals | None | $125 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Livtencity | $122 | 1 payment
|
| Sanofi-Aventis U.S. | Thymoglobulin | $121 | 1 payment
|
| Novartis Pharmaceuticals | None | $75 | 1 payment
|
| Veloxis Pharmaceuticals | Envarsus | $65 | 2 payments
|
2022: $545
| IBSA Pharma | Tirosint | $159 | 3 payments
|
| CSL Behring | None | $125 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Livtencity | $124 | 1 payment
|
| Insulet | Omnipod | $91 | 4 payments
|
| Veloxis Pharmaceuticals | Envarsus | $30 | 1 payment
|
| Dexcom | Dexcom G6 Transmitter | $16 | 1 payment
|
2021: $157
| Alexion Pharmaceuticals | None | $125 | 1 payment
|
| Insulet | Omnipod | $32 | 2 payments
|
2019: $1,431
| Fresenius USA Marketing | None | $1,431 | 3 payments
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| CSL Behring · A Pivotal Phase 3 Trial To Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody-Mediated Rejection in Kidney Transplant Recipients · 2024 | Their institution | $62,002 |
| CSL Behring · A Pivotal Phase 3 Trial To Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody-Mediated Rejection in Kidney Transplant Recipients · 2022 | Their institution | $2,219 |
| Novartis Pharmaceuticals Corporation · A Multicenter, Single-Arm, Open Label Trial To Evaluate Efficacy and Safety of Oral, Twice Daily Lnp023 in Adult Ahus Patients Who Are Naive To Complement Inhibitor Therapy · 2024 | Their institution | $723 |
| CSL Behring · A Pivotal Phase 3 Trial To Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody-Mediated Rejection in Kidney Transplant Recipients · 2023 | Their institution | $620 |
| Novartis Pharmaceuticals Corporation · A Multicenter, Single-Arm, Open Label Trial To Evaluate Efficacy and Safety of Oral, Twice Daily Lnp023 in Adult Ahus Patients Who Are Naive To Complement Inhibitor Therapy · 2023 | Their institution | $53 |
Professional record
- NPI
- 1356755532
- Licence
- CA A161369California A161369: Current · expires 2027-03-31
- Trained
- Eastern Virginia Medical School, 2014
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RN0300X (207RN0300X); Internal medicine (207R00000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2014-06-16
- NPI last updated
- 2024-11-04
- NPI record certified
- 2024-10-29
This is when the NPI record was last certified, not a medical board exam.